The pathology of hypertrophic cardiomyopathy

Histopathology

Volumn 44, Issue 5, 2004, Pages 412-427

  Hughes, S E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autopsy; Hypertrophic cardiomyopathy; Myocyte disarray; Sudden cardiac death

Indexed keywords

CARDIAC MYOSIN; PROTEIN DERIVATIVE; TROPONIN T;

ALLELE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENDOCARDIUM; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HETEROZYGOTE DETECTION; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MICROMORPHOLOGY; MISSENSE MUTATION; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SARCOMERE; VALVULAR HEART DISEASE;

AUTOPSY; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY VESSELS; DEATH, SUDDEN, CARDIAC; FEMALE; FIBROSIS; GENETIC SCREENING; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MUTATION; MYOCYTES, CARDIAC;

EID: 2642531954     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01835.x     Document Type: Review

References (155)

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995; 92; 785-789.
2. Maron BJ, Roberts WC. Cardiomyopathies in the first two decades of life. Cardiovasc. Clin. 1981; 11; 35-78.
3. Charron P, Carrier L, Dubourg O et al. Penetrance of familial hypertrophic cardiomyopathy. Genet. Couns. 1997; 8; 107-114.
4. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N. Engl. J. Med. 1986; 315; 610-614.
5. Pomerance A, Davies M. Pathological features of hypertrophic obstructive cardiomyopathy (HOCM) in the elderly. Br. Heart J. 1975; 37; 305-312.
6. Wigle ED. Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 1995; 10; 299-305.
7. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J, Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and haemodynamic features. Am. J. Cardiol. 1981; 47; 532-538.
8. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982; 65; 1388-1394.
9. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1989; 13; 820-823.
10. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342; 1778-1785.
11. Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br. Heart. J. 1990; 63; 308-310.
12. Maron BJ, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation 2000; 102; 858-864.
13. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N. Engl. J. Med. 1987; 316; 844-852.
14. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischaemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993; 22; 796-804.
15. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic and pathological profiles. JAMA 1996; 276; 199-204.
16. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989; 80; 1489-1492.
17. Shah PM, Adelman AG, Wigle ED et al. The natural and (unnatural) history of hypertrophic obstructive cardiomyopathy. A multicenter study. Circ. Res. 1974; 35 (Suppl. II); 179-195.
18. McKenna W, Deanfield J. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch. Dis. Child. 1984; 59; 971-975.
19. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J. Am. Coll. Cardiol 1995; 26; 1529-1536.
20. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281; 650-655.
21. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am. J. Cardiol. 1993; 72; 939-943.
22. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995; 92; 2488-2495.
23. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002; 287; 1308-1320.
24. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999; 33; 206-211.
25. Wigle ED. Cardiomyopathy. The diagnosis of hypertrophic cardiomyopathy. Heart 2001; 86; 709-714.
26. Waller BF, Maron BJ, Epstein SE, Roberts WC. Transmural myocardial infarction in hypertrophic cardiomyopathy: a cause of conversion from left ventricular asymmetry to symmetry and from normal-sized to dilated left ventricular cavity. Chest 1981; 79; 461-465.
27. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy - pathology and pathogenesis. Histopathology 1995; 26; 493-500.
28. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 1958; 20; 1-8.
29. Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. Am. J. Cardiol. 1981; 48; 258-262.
30. Schwammenthal E, Nakatani S, He S et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy. Mismatch of posterior to anterior leaflet length and mobility. Circulation 1998; 98; 856-865.
31. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992; 85; 1651-1660.
32. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 1991; 84; 1188-1197.
33. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 1998; 98; 2505-2508.
34. Goor D, Lillihei CW, Edwards JE. The 'sigmoid septum'. Variation in the contour of the left ventricular outlet. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1969; 107; 366-376.
35. Waller BF, Roberts WC. Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over. Am. J. Cardiol. 1983; 51; 403-421.
36. Waller BF. The old-age heart: normal aging changes which can produce or mimic cardiac disease. Clin. Cardiol. 1988; 11; 513-517.
37. Krasnow N. Subaortic septal bulge simulates hypertrophic cardiomyopathy by angulation of the septum with age, independent of focal hypertrophy. An echocardiographic study. J. Am. Soc. Echocardiogr. 1997; 10; 545-555.
38. Dalldorf FG, Willis PW. Angled aorta ('sigmoid septum') as a cause of hypertrophic subaortic stenosis. Hum. Pathol. 1985; 16; 457-462.
39. Litovsky SH, Rose AG. Clinicopathologic heterogeneity in hypertrophic cardiomyopathy with regard to age, asymmetric septal hypertrophy, and concentric hypertrophy beyond the pediatric age group. Arch. Pathol. Lab. Med. 1998; 122; 434-441.
40. Lai ZY, Shih CM, Chang NC, Wang TC. Clinical and morphologic features of hypertrophic cardiomyopathy in elderly patients 85 years or older. Jpn Heart J. 1999; 40; 155-164.
41. Wigle ED, Sasson Z, Henderson MA et al. Hypertrophic cardiomyopathy. The importance of the site and extent of hypertrophy. A review. Prog. Cardiovasc. Dis. 1985; 28; 1-83.
42. Falicov RE, Resnekov L, Bharati S, Lev M. Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. Am. J. Cardiol. 1976; 37; 432-437.
43. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J. Am. Coll. Cardiol. 1987; 9; 288-294.
44. Maron BJ, Hauser RG, Roberts WC. Hypertrophic cardiomyopathy with left ventricular apical diverticulum. Am. J. Cardiol. 1996; 77; 1263-1265.
45. Barbosa MM, Coutinho AH, Motta MS, Fortes PR, Roza AZ, God EM. Apical hypertrophic cardiomyopathy: a study of 14 patients and their first degree relatives. Int. J. Cardiol. 1996; 56; 41-51.
46. Ando H, Imaizumi T, Urabe Y, Takeshita A, Nakamura M. Apical segmental dysfunction in hypertrophic cardiomyopathy: subgroup with unique clinical features. J. Am. Coll. Cardiol. 1990; 16; 1579-1588.
47. Maron BJ, Bonow RO, Seshagiri TN, Roberts WC, Epstein SE. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). Am. J. Cardiol. 1982; 49; 1838-1848.
48. Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle: echocardiographic and ultrasono-cardiotomographic study. Jpn Heart. J. 1976; 17; 611-629.
49. Webb JG, Sasson Z, Rakowski H, Liu P, Wigle ED. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J. Am. Coll. Cardiol. 1990; 15; 83-90.
50. Seiler C, Jenni R., Vassali G, Turina M, Hess OM. Left ventricular chamber dilatation in hypertrophic cardiomyopathy, related variables and prognosis in patients with medical and surgical therapy. Br. Heart. J. 1995; 74; 508-516.
51. Hina K, Kusachi S, Iwasaki K et al. Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. Clin. Cardiol. 1993; 16; 403-407.
52. Yutani C, Imakita M, Ishibashi-Ueda H et al. Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. Am. Heart J. 1985; 109; 545-553.
53. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1986; 8; 545-557.
54. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Morphologic evidence for 'small vessel disease' in patients with hypertrophic cardiomyopathy. Z. Kardiol. 1987; 76 (Suppl. 3); 91-100.
55. Stollberger C, Finsterer J. Reversal of dilated to hypertrophic cardiomyopathy after alcohol abstinence. Clin. Cardiol. 1998; 21; 365-367.
56. Fujino N, Shimizu M, Ino H et al. A novel mutation of Lys273Glu in the cardiac troponin T gene shows high penetrance and transition from hypertrophic to dilated cardiomyopathy. Am. J. Cardiol. 2002; 89; 29-33.
57. Okamoto S, Ozaki M, Konishi T, Nakano T. A case report of siblings with hypertrophic cardiomyopathy that progressed to dilated cardiomyopathy - case reports. Angiology 1993; 44; 406-411.
58. Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation 1992; 85; 157-163.
59. Rose AG. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy. Histopathology 1984; 8; 395-406.
60. Maron BJ, Henry WL, Roberts WC, Epstein SE. Comparison of echocardiographic and necropsy measurements of ventricular wall thickness in patients with and without disproportionate septal thickening. Circulation 1977; 55; 341-346.
61. Unverferth DV, Baker PB, Pearce LI, Lautman J, Roberts WC. Regional myocyte hypertrophy and increased interstitial myocardial fibrosis in hypertrophic cardiomyopathy. Am. J. Cardiol. 1987; 59; 932-936.
62. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979; 59; 689-706.
63. Tanaka M, Fujiwara H, Onodera T et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br. Heart J. 1986; 55; 575-581.
64. Maron BJ, Wolfson JK, Roberts WC. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am. J. Cardiol. 1992; 70; 785-790.
65. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 2000; 35; 36-44.
66. Davies MJ. The current status of myocardial disarray in hypertrophic cardiomyopathy. Br. Heart J. 1984; 51; 361-363.
67. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis and small vessel disease. Heart 2000; 84; 476-482.
68. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981; 63; 882-894.
69. Maron BJ, Sato N, Roberts WC, Edwards JE, Chandra RS. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum. Comparison of fetuses and infants with and without congenital heart disease and patients with hypertrophic cardiomyopathy. Circulation 1979; 60; 685-696.
70. Bulkley BH, Weisfeldt ML, Hutchins GM. Asymmetric septal hypertrophy and myocardial fiber disarray. Features of normal, developing and malformed hearts. Circulation 1977; 56; 292-298.
71. Van der Bel-Kahn J. Muscle fibre disarray in common heart diseases. Am. J. Cardiol. 1977; 40; 355-364.
72. Becker AE, Caruso G. Myocardial disarray. A critical review. Br. Heart J. 1982; 47; 527-538.
73. St John Button MG. Lie JT, Anderson KR, O'Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br. Heart J. 1980; 44; 433-443.
74. Sepp R, Severs NJ, Gourdie RG. Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart 1996; 76; 412-417.
75. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy. Histological features of sudden death in cardiac troponin T disease. Circulation 2001; 104; 1380-1384.
76. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1991; 17; 1343-1351.
77. Takemura G, Takatsu Y, Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart 1998; 79; 78-85.
78. Iida K, Yutani C, Imakita M et al. Comparison of percentage area of myocardial fibrosis and disarray in patients with classical form and dilated phase of hypertrophic cardiomyopathy. J. Cardiol. 1998; 32; 173-180.
79. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum. Pathol. 2000; 31; 988-998.
80. Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch. 1997; 431; 265-273.
81. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy - a risk factor for sudden death. N. Engl. J. Med. 1998; 339; 1201-1209.
82. Kitazume H, Kramer JR, Krauthamer D, El Tobgi S, Proudfit WI, Sones FM. Myocardial bridges in obstructive hypertrophic cardiomyopathy. Am. Heart J. 1983; 106; 131-135.
83. Thierfelder L, Watkins H, MacRae C et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77; 701-712.
84. Towbin JA. Molecular genetics of hypertrophic cardiomyopathy. Curr. Cardiol. Report 2000; 2; 134-140.
85. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 2001; 33; 655-670.
86. Marian AJ, Salek L, Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med. 2001; 92; 435-451.
87. Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain missense mutation. Cell 1990; 62; 999-1006.
88. Poetter K, Jiang H, Hassanzadeh S et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 1996; 13; 63-69.
89. Flavigny J, Richard P, Isnard R et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J. Mol. Med. 1998; 76; 208-214.
90. Bonne G, Carrier L, Bercovici J et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat. Genet. 1995; 11; 434-437.
91. Watkins H, Conner D, Thierfelder L et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 1995; 11; 434-437.
92. Niimura H, Bachinski LL, Sangwatanaroj S et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 1998; 338; 1248-1257.
93. Mogensen J, Klausen IC, Pedersen AK et al. α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J. Clin. Invest. 1999; 103; R39-R43.
94. Watkins H, McKenna WJ, Thierfelder L et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 1995; 332; 1058-1064.
95. Lang R, Gomes AV, Zhao J, Housmans PR, Miller T, Potter JD. Functional analysis of a troponin I (Arg145Gly) mutation associated with familial hypertrophic cardiomyopathy. J. Biol. Chem. 2002; 277; 11670-11678.
96. Kimura A, Harada H, Park JE et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 1997; 16; 379-382.
97. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Biophys. Res. Commun. 1999; 262; 411-417.
98. Niimura H, Patton KK, McKenna WJ et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105; 446-451.
99. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ. Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 2001; 17; 524.
100. Bonne G, Carrier L, Richard P, Hainque B, Schwarz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ. Res. 1998; 83; 580-593.
101. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J. Clin. Invest. 1992; 90; 1666-1671.
102. Forissier J-F, Richard P, Briault S et al. First description of germline mosaicism in familial hypertrophic cardiomyopathy. J. Med. Genet. 2000; 37; 132-134.
103. MacRae CA, Ghaisas N, Kass S et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J. Clin. Invest. 1995; 96; 1216-1220.
104. Gollob MH, Green MS, Tang AS et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 2001; 344; 1823-1831.
105. Arad M, Benson DW, Perez-Atayde AR et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 2002; 109; 357-362.
106. Blair E, Redwood C, Ashrafian H et al. Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 2001; 10; 1215-1220.
107. Moolman JC, Corfield VA, Posen B et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 1997; 29; 549-555.
108. Maron BJ, Niimura H, Casey SA et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J. Am. Coll. Cardiol. 2001; 38; 331-334.
109. Charron P, Dubourg O, Desnos M et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998; 97; 2230-2236.
110. Mörner S, Richard P, Kazzam E, Hainque B, Schwarz K, Waldenstrom A. Deletion in the cardiac troponin I gene in a family from Northern Sweden with hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 2000; 32; 521-525.
111. Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 2003; 111; 209-216.
112. Coviello DA, Maron BJ, Spirito P et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a 'hot spot' in the alpha-tropomyosin gene. J. Am. Coll. Cardiol. 1997; 29; 635-640.
113. Karibe A, Tobacman LS, Strand J et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, and abnormal myosin cycling, and a poor prognosis. Circulation 2001; 103; 65-71.
114. Watkins H, Rosenzweig T, Hwang DS et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 1992; 326; 1106-1114.
115. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr. Opin. Cell. Biol. 1996; 8; 97-105.
116. Solomon SD, Wolff S, Watkins H et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J. Am. Coll. Cardiol. 1993; 22; 498-505.
117. Ko Y, Tang TK, Chen JJ, Hshieh YY, Wu CW, Lien WP. Idiopathic hypertrophic cardiomyopathy in identical twins. Morphological heterogeneity of the left ventricle. Chest 1992; 102; 783-785.
118. Brugada R, Kelsey W, Lechin M et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J. Invest. Med. 1997; 45; 542-551.
119. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355; 58-60.
120. Li R-K, Li G, Mickle DA et al. Overexpression of transforming growth factor-β1 and insulin-like growth factor-1 in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997; 96; 874-881.
121. Hasegawa K, Fujiwara H, Koshiji M et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996; 27; 259-264.
122. Marian AJ, Yu Q, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism is associated with hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342; 1085-1086.
123. Lechin M, Quinones M, Omran A et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995; 92; 1808-1812.
124. Tesson F, Dufour C, Moolman JC et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease mutation. J. Mol. Cell. Cardiol. 1997; 29; 831-838.
125. Geisterfer-Lowrance AAT, Christe M, Conner DA et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996; 272; 731-734.
126. Dalloz F, Osinska H, Robbins J. Manipulating the contractile apparatus: genetically defined animal models of cardiovascular disease. J. Mol. Cell. Cardiol. 2001; 33; 9-25.
127. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc. Res. 1999; 44; 20-36.
128. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy: a study of 204 cases (1996-2000). Cardiovasc. Pathol. 2003; 12; 149-158.
129. Tazelaar HD, Billingham ME. The surgical pathology of hypertrophic cardiomyopathy. Arch. Pathol. Lab. Med. 1987; 111; 257-260.
130. Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy not associated with hypertrophic cardiomyopathy: a study of 98 cases (1996-2000). Cardiovasc. Pathol. 2003; 12; 207-215.
131. Oh JK, Tajik AJ, Edwards WD, Bresnahan JF, Kyle RA. Dynamic left ventricular outflow tract obstruction in cardiac amyloidosis detected by continuous-wave Doppler echocardiography. Am. J. Cardiol. 1987; 59; 1008-1010.
132. Glazier JJ, Mortimer G, Daly KM. A clinical role for right ventricular endomyocardial biopsy. Ir. Med. J. 1989; 82; 153-155.
133. Hoshino T, Fujiwara H, Kawai C, Hamashima Y. Diagnostic value of disarray in endomyocardial biopsy specimens in hypertrophic cardiomyopathy: a critical report based on distribution of disarray in the subendocardial region of autopsied hearts. Jpn. Circ. J. 1982; 46; 1281-1291.
134. Tanaka H, Adachi K, Yamashita Y, Toshima H, Koga Y. Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy. J. Cardiol. 1988; 18; 705-718.
135. Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. Fabry disease in patients with hypertrophic cardiomyopathy (HCM). Z. Kardiol. 2002; 91; 992-1002.
136. Sachdev B, Elliott PM. Isolated cardiac manifestations in Fabry disease: the UK experience. Acta. Paediatr. Suppl. 2002; 439; 28-30.
137. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105; 1407-1411.
138. Nakao S, Takenaka T, Maeda M et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N. Engl. J. Med. 1995; 333; 288-293.
139. Linhart A, Palecek T, Bultas J et al. New insights in cardiac structural changes in patients with Fabry's disease. Am. Heart J. 2000; 139; 1101-1108.
140. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003; 89; 929-930.
141. Nagueh SF. Fabry disease. Heart 2003; 89; 819-820.
142. Frustaci A, Chimenti C, Ricci R et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N. Engl. J. Med. 2001; 345; 25-32.
143. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha galactosidase A replacement in Fabry disease. N. Engl. J. Med. 2001; 345; 9-16.
144. Maron BJ, Ferrans VJ, Roberts WC. Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. Am. J. Pathol. 1975; 79; 387-434.
145. Arbustini E, Fasani R, Morbini P et al. Coexistence of mitochondrial DNA and β myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure. Heart 1998; 80; 548-558.
146. Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am. J. Cardiol. 1998; 82; 774-778.
147. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart. J. 1985; 53; 412-416.
148. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87; 169-176.
149. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000; 83; 326-331.
150. Sigwart U. Non-surgical myocardial reduction for hypertrophic cardiomyopathy. Lancet 1995; 346; 211-214.
151. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999; 33; 1596-1601.
152. Maron BJ, Shen W-K, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342; 365-373.
153. Vincent GM. Role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome. Heart 2001; 86; 12-14.
154. Ommen SR, Tajik AJ. Hypertrophic cardiomyopathy. From bedside to bench...and now back again? Circulation 2001; 104; 126-127.
155. Maron BJ, Moller JH, Seidman CE et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. Circulation 1998; 98; 1460-1471.